Research
Evidence reviews of the drugs sold online — semaglutide, tirzepatide, and what the trials behind them actually measured. No secondary summaries: every claim traced to the trial, the label, or the paper of record.
Every published price, lowest first
Ranked on the standing month-to-month rate — the only number that survives contact with month two, and the one sellers advertise least.
Head-to-head comparisons
Two sellers side by side on price, dose disclosure, format and states served — scored on the same rubric.
260 articles
- Safety
GLP-1 and IBS: Why the Drug Name Matters
An experimental GLP-1 analog reduced IBS pain in a small trial. That does not establish that Ozempic, Wegovy, or Zepbound treats irritable bowel syndrome.
9 min read - Safety
GLP-1 and Kidney Stones: What the Urine Studies Show
Small studies do not show a clear worsening of stone-forming urine chemistry, but that is different from proving semaglutide or tirzepatide prevents kidney stones.
9 min read - Safety
GLP-1 and Lupus: Small Studies, Important Limits
An 18-person lupus cohort and a separate suspected drug-induced lupus case answer different questions. Neither establishes that GLP-1 medicines treat lupus or quantifies a causal risk.
9 min read - Evidence
GLP-1 and SGLT2 Inhibitors: When Two Diabetes Drugs Help
Combination treatment can improve glucose and weight outcomes. Heart and kidney benefits appear to persist, but the smaller subgroups and one uncertain kidney comparison matter.
9 min read - Safety
GLP-1 Blood Tests: What to Ask Before and During Treatment
Glucose, kidney function, thyroid screening and testing fees: how to understand a GLP-1 lab plan without assuming everyone needs the same panel.
9 min read - Evidence
Not Losing Weight on Tirzepatide? What Late Response Means
A slow start is not always treatment failure. What a SURMOUNT-1 analysis found, who its 90% result applies to, and what to discuss before another refill.
9 min read - Evidence
SURMOUNT-MAINTAIN: Can a Lower Tirzepatide Dose Hold Weight Loss?
After 60 weeks of treatment, lowering tirzepatide to 5 mg preserved more weight loss than stopping, but less than continuing 10 or 15 mg. The rescue rule changes how to read the results.
9 min read - Evidence
Ozempic and Weed: What Is Known About GLP-1s and Cannabis
No interaction is listed on the semaglutide or tirzepatide labels. The overlap is in the stomach, the appetite and the vomiting, and the cannabis use disorder cohorts are weaker than their headline.
9 min read - Formats
GLP-1 Patches: What They Contain and Why None Is a Drug
Patches sold as “GLP-1” contain botanicals like berberine, not semaglutide or tirzepatide. No transdermal GLP-1 is FDA-approved, and the drug molecule is eight to ten times too large to pass through skin.
8 min read - Evidence
GLP-1 Supplements and Berberine: What the Trials Show
Berberine, the supplement sold as "nature's Ozempic," pools to −0.88 kg across 23 randomized trials. Semaglutide's placebo-adjusted loss in STEP 1 was −12.7 kg. Fiber, Akkermansia and yerba mate, measured the same way.
8 min read - Evidence
How to Get a GLP-1 Prescription for Weight Loss
Who the Wegovy and Zepbound labels cover, why Ozempic is the wrong name to ask for, the three routes to a prescriber, and what each costs. In one health system 45% of adults qualified and 1.4% of them were prescribed.
9 min read - Evidence
Wegovy Pill: Dosing, Results, Side Effects and Cost
Wegovy is both a weekly injection and, since December 22, 2025, a once-daily 25 mg semaglutide tablet. Its trial landed within about a point of the pen on average, and the gap sits almost entirely among people who barely responded.
8 min read - Evidence
ACHIEVE-1 Explained: Where the Oral GLP-1 Curve Stops
Orforglipron's glycemic effect finished by 12 mg — 36 mg added 0.01 percentage points of HbA1c — while weight loss kept climbing to −7.6%. And the trial's celebrated 4.4% to 7.8% quit rate is the friendliest in its own program by a factor of three.
9 min read - Safety
Bacteriostatic Water and Reconstitution: What the Diluent Label Actually Says
Bacteriostatic water carries benzyl alcohol at 9 or 11 mg/mL and a neonatal contraindication — and its own label tells you not to store a reconstituted drug unless that drug's manufacturer says you can.
10 min read - Evidence
Anti-Drug Antibodies and GLP-1 Drugs: What the Labels Report and What They Never Tested
Tirzepatide has the highest antibody rate in the class at 64.5% and loses no efficacy. Exenatide hit 61% and high titers cost patients HbA1c. Positivity is not the number that matters.
11 min read - Safety
GLP-1s and Water Pills: The Dose That Stops Being Right
Six GLP-1 labels use the word diuretic zero times. All six warn about volume depletion, which is what a diuretic does on purpose. In two heart failure trials the loop diuretic dose fell 17% over a year on semaglutide while rising on placebo — and three published cases describe an electrolyte moving far enough to require hospital care.
10 min read - Safety
GLP-1 and Difficulty Swallowing: What the Labels Actually Say
Dysphagia is printed three times on every label in this class, and all twenty-one appearances are the thyroid-tumor warning rather than a side effect. The two 2026 manometry studies of the esophagus reach opposite conclusions, and no study reports an incidence.
9 min read - Safety
GLP-1s and Seizure Medications: Nobody Has Drawn a Level
Phenytoin can be tipped into intoxication by a 10% change in dose, and carbamazepine is titrated to a 4 to 12 mcg/mL window. No GLP-1 label names either one, and no study has ever measured an antiseizure drug concentration in a person taking one of these injections. What has been counted is seizures — and they went down.
9 min read - Evidence
GLP-1s and Gout: Urate Fell, Attacks Did Not
Tirzepatide lowered serum urate by 0.95 mg/dL against placebo in a randomized trial of 2,539 adults. Across 22 randomized outcome trials and 173,498 patients, the same class changed gout risk not at all — while SGLT2 inhibitors halved it.
9 min read - Safety
GLP-1 and Hiccups: On One Label, With No Number Attached
Hiccups are printed as an adverse reaction on exactly one of seven current labels in this class, and no percentage is attached to them anywhere. The reporting database holds 205 semaglutide reports and 107 tirzepatide reports, and the published literature holds nothing at all.
9 min read - Safety
GLP-1s and Lithium: The Interaction No Label Mentions
Lithium's therapeutic range is 0.8 to 1.2 mEq/L and toxicity starts at 1.5. Its label names volume depletion, dehydration and diarrhea as things that raise a level — the exact events a GLP-1 causes while a dose is being escalated. Four published reports describe it happening. Six GLP-1 labels mention lithium zero times.
9 min read - Safety
GLP-1 and Micronutrients: Inferred Almost Everywhere, Measured Almost Nowhere
Across 19 pooled randomized trials, investigators recorded malnutrition in 0.12% of participants while a blood test found the marker in 2.90%, against 1.77% on placebo. Almost everything else said about vitamins on these drugs is borrowed from bariatric surgery.
10 min read - Formats
GLP-1 Access on TRICARE and at the VA: The Rule and the Override
Federal law bars TRICARE from treating obesity as a sole condition, and a 2017 authority written into the regulation covers it anyway under two plans — through a network provider. On the VA national formulary, two diabetes injectables are carried and ten other GLP-1 entries are not.
10 min read - Evidence
GLP-1s and Multiple Sclerosis: One 28-Person Trial
The entire human record is one open-label trial of 28 people on a diabetes-sized dose, plus two clinic series totaling 109 patients. Neurofilament light and MRI volume did not move, and no label mentions the disease at all.
10 min read - Safety
GLP-1s and the Pill: Why Only One Label Says Use Backup
The tirzepatide labels carry a section headed Contraception and a four-week backup instruction. The semaglutide label does not contain the word — it lists ethinyl estradiol and levonorgestrel among the drugs nothing happened to. Five molecules were tested; here is what each one actually did.
9 min read - Evidence
GLP-1s and Psoriasis: What the One Large Trial Measured
A 274-person phase 3b trial gave everyone ixekizumab and half of them tirzepatide. Its headline endpoint required weight loss to be met — and on skin clearance alone the gap was 11.6 points, on a confidence interval running down to 0.3.
9 min read - Evidence
GLP-1s and Rheumatoid Arthritis: No Trial, One Chart Review
Not one randomized trial of this class in rheumatoid arthritis has been published, and not one is registered. The only clinical study compared 173 patients who took the drug against 42 who were prescribed it and did not.
10 min read - Formats
Beyond-Use Dates on Compounded GLP-1: What the Date on the Vial Means
The longest refrigerated beyond-use date in FDA's default table is 42 days, it only applies below 1,000 sterile units a half-year, and the clock starts at compounding — not when your twelve-week box arrives.
10 min read - Formats
GLP-1 Half-Life and Steady State: What the Labels Say
Semaglutide's labeled half-life is about a week, tirzepatide's five to six days, liraglutide's 13 hours and exenatide's 2.4 hours. Four to five half-lives reaches steady state and clears a drug again — but the same semaglutide half-life carries a five-week persistence window on one label and five to seven weeks on another.
9 min read - Evidence
PIONEER 4 Explained: The Semaglutide Tablet Against an Injection
PIONEER 4 randomized 711 people to oral semaglutide 14 mg, liraglutide 1.8 mg or placebo for 52 weeks. The preregistered superiority test against liraglutide returned p = 0.0645 — and on the trial's own satisfaction questionnaire the injection scored 0.73 against the tablet's 0.72.
10 min read - Evidence
SCALE Obesity and Prediabetes Explained: Liraglutide 3.0 mg
SCALE randomized 3,731 adults 2:1 to liraglutide 3.0 mg or placebo for 56 weeks. Weight fell 8.4 kg against 2.8 — a difference of 5.6 kg — while 28% of the drug arm and 36% of the placebo arm never reached week 56, and a randomized withdrawal inside the trial measured what 12 weeks off the drug cost.
10 min read - Safety
Semaglutide Sodium and Acetate: Why the Salt Forms Fail the Compounding Test
FDA did not say the salts are a different active moiety — under 21 CFR 314.3 they share one. It said they are different active ingredients, and that is the word the statute turns on.
10 min read - Evidence
STEP 6 Explained: Semaglutide in Japan and South Korea
STEP 6 randomized 401 adults in Japan and South Korea four ways across two semaglutide doses and pooled placebo. Weight fell 13.4% against 1.9%, a difference of 11.06 points — in a cohort averaging 87.5 kg, 63% men, with only six non-completions in 68 weeks.
9 min read - Evidence
STEP 7 Explained: A 44-Week Clock and a Busy Placebo Arm
STEP 7 randomized 375 adults across China, Hong Kong, Brazil and South Korea 2:1 to semaglutide 2.4 mg or placebo for 44 weeks. Weight fell 12.5% against 3.6% — a difference of 8.47 points, on the shortest schedule in the program and against a control arm that outlost the 68-week trials it is usually compared with.
9 min read - Evidence
STEP TEENS Explained: The 16% Is a BMI Change, Not a Weight Change
STEP TEENS randomized 201 adolescents 2:1 to semaglutide 2.4 mg or placebo for 68 weeks after a 12-week lifestyle run-in. BMI fell 16.2% against 0.1% — but body weight fell 14.8% while the placebo group gained 2.3%, because adolescents grow.
10 min read - Evidence
SUMMIT Explained: The HFpEF Trial Powered on Events
Tirzepatide cut cardiovascular death or worsening heart failure by a hazard ratio of 0.62 in 731 patients — while cardiovascular death alone ran 8 against 5 the other way, and serious adverse events came out even at 96 against 94.
10 min read - Evidence
SURMOUNT-5 Explained: The Head-to-Head, Read Properly
An open-label trial in 751 Americans found a 6.5-point weight advantage for tirzepatide, 95% CI 4.9 to 8.1 — with an identical side-effect table, six discontinuations in each arm, and a most-quoted maximum-dose figure that is a model output rather than an observed result.
9 min read - Evidence
SURPASS-1 Explained: Tirzepatide Alone Against Placebo
SURPASS-1 randomized 478 drug-naive adults with type 2 diabetes to tirzepatide 5, 10 or 15 mg or placebo for 40 weeks. Glycated hemoglobin fell 1.87, 1.89 and 2.07 points — two of those doses are 0.02 apart — while serious adverse events ran 5, 2 and 1 against 3 on placebo.
10 min read - Evidence
SURPASS-5 Explained: Tirzepatide Added to Insulin
SURPASS-5 added tirzepatide or placebo to titrated insulin glargine in 475 adults for 40 weeks. The placebo arm needed 75% more insulin to move — and hypoglycemia below 54 mg/dL ran 0.49, 0.66 and 0.38 episodes a year on tirzepatide against 0.51 on placebo.
10 min read - Evidence
SURPASS-AP-Combo Explained: Tirzepatide Against Insulin
The trial that compared tirzepatide with titrated insulin glargine rather than placebo: HbA1c down 2.49 points against 0.95, weight down 7.2 kg while the insulin arm gained 1.5 kg — and a quarter of its 917 participants were not overweight.
10 min read - Evidence
ATTAIN-2 Explained: An Oral GLP-1 in Type 2 Diabetes
ATTAIN-2 randomized 1,613 adults with obesity and type 2 diabetes to a once-daily orforglipron tablet or placebo for 72 weeks. The top dose beat placebo by 7.1 percentage points on weight and 1.65 points on glycated hemoglobin — and by 0.07 mm Hg on diastolic blood pressure, which is to say not at all.
9 min read - Evidence
CagriSema vs Tirzepatide: What Cannot Be Compared
No trial has ever given one group cagrilintide-semaglutide and another tirzepatide. Across four separate phase 3 trials the placebo-subtracted gaps are 17.3 against 17.8 points without diabetes and 10.4 against 11.6 with it — and the pooled rankings reverse depending on the endpoint chosen.
9 min read - Safety
What Rules Govern How a GLP-1 Can Be Advertised
FDA's promotion office lists compounded drugs among the promotion it does not regulate. The one statutory advertising ban on compounded drugs was held unconstitutional in 2002 and deleted from the law in 2013 — leaving the FTC's general deception and substantiation rules as what applies.
10 min read - Evidence
Amylin Analogs: What the Class Has Actually Shown
Amylin is the second satiety lever, and one analog of it has ever been approved in the United States — pramlintide, which produced 3.7% placebo-corrected weight loss over 16 weeks and is now recorded as discontinued. The unapproved analogs report up to 20%.
10 min read - Safety
GLP-1s and Breastfeeding: What Has Actually Been Measured
The tirzepatide label reports milk measurements in 11 women. The semaglutide injection label reports none. The one semaglutide formulation with a published lactation study is the one that advises against nursing — and the reason is the absorption enhancer, not the drug.
8 min read - Evidence
GLP-1s and Dialysis: What the Labels Claim and What Was Tested
Four labels in one class give four different answers about end-stage kidney disease. The reassuring one rests on eight dialysis patients — and drug exposure peaks in moderate impairment, not at the bottom of the range.
9 min read - Evidence
GLP-1s, Fertility and IVF: The Washout and the Missing Endpoint
The semaglutide labels ask for a two-month gap before conception and the tirzepatide labels ask for nothing. Meanwhile the one randomized test of the premise cut metabolic syndrome from 52.8% to 32.2% and delivered fewer healthy live births.
9 min read - Evidence
GLP-1 and Libido: What No Trial Measured
No randomized trial of semaglutide, tirzepatide or liraglutide has ever measured sexual desire, and none of the six current labels uses the word. The evidence that exists points in four directions at once.
9 min read - Evidence
GLP-1s and Metabolic Syndrome: A Cluster That Moves Unevenly
Across 7,805 participants the odds of the five metabolic syndrome criteria fell by amounts ranging from 96% to 34%. The syndrome itself predicted death less well than raised fasting glucose alone — and no label in the class names it.
9 min read - Evidence
GLP-1 Muscle Cramps: A Word on No Label
Cramp, myalgia and hypokalemia appear zero times across the six current labels in this class, at thresholds that reach down to 2% — and in the one population where cramping was studied with blood drawn, potassium and magnesium ran higher in the people who cramped.
8 min read - Safety
Why a Pharmacy Needs a License in Your State
The prescriber's license is only half of it. Seven state statutes require an out-of-state pharmacy to hold a nonresident license before it may mail anything in — and Texas will not issue one to a sterile compounder its own board has not inspected.
10 min read - Evidence
GLP-1 and Sleep Quality: The Unnumbered Endpoint
The tirzepatide label gives the breathing count, the hypoxic burden and the weight loss each a confidence interval. The one endpoint describing how a person's sleep felt gets a single sentence and no figure at all.
9 min read - Evidence
GLP-1 and Smell Changes: The Test Moves the Other Way
No GLP-1 label records an olfactory term, though all six record dysgeusia. Reporting databases give olfactory abnormality a reporting odds ratio of 2.44 — while every prospective olfactory test under these drugs found smell improved.
8 min read - Formats
Biosimilar or Generic? Where a GLP-1 Peptide Sits
Federal regulation draws the line at 40 amino acids, and the GLP-1 peptides sit just underneath it — so their copies are generics, not biosimilars. The brand liraglutide is grown in yeast and its generic is chemically synthesized, and the register calls them equivalent.
9 min read - Formats
GLP-1 Generics: The Dates, and What Liraglutide Did
Liraglutide has eleven approved generics and two years of federal pricing data behind them. The diabetes regimen got 63.6% cheaper to buy and the weight-management regimen 45.3%, the brand never moved, and the first discount was only 16.6%.
9 min read - Safety
How to Read a Certificate of Analysis for a Compounded GLP-1
The only certificate of analysis federal law requires in either compounding route describes the raw powder, is addressed to the pharmacist, and predates the vial entirely — and the row a buyer finds most reassuring is the one the FDA tells compounders not to lean on.
10 min read - Safety
State Boards, Complaints, and What You Can Look Up
A complaint to a state board is confidential, the investigation is confidential, and a case closed without action never appears at all. In 2017 state medical boards disciplined 4,081 physicians out of nearly a million licensed — so a clean lookup is the ordinary result, not a clean record.
10 min read - Safety
The Consent and Terms You Sign for a GLP-1
Four documents pass under one checkbox, and the two that decide a dispute are the two nobody reads. Across 286 seller write-ups here, a cancellation term is recorded 28 times and a dispute-resolution term zero times — which measures what sellers put near the price, not what their contracts contain.
10 min read - Formats
What a 503B Outsourcing Facility Actually Is
A status a company elects into, pays about $20,000 a year to keep, and files a production report twice a year to maintain — and whose bulk-ingredient list, twelve years on, contains five substances, none of them injectable.
9 min read - Safety
What a GLP-1 Telehealth Intake Actually Asks
Sort the screening questions by what kind of fact they seek — declared, measured or observed — and a questionnaire turns out to be strongest where the label is absolute, and structurally blind everywhere a number is required.
8 min read - Safety
What Happens to Your Data in Cash-Pay GLP-1 Telehealth
HIPAA reaches a health care provider only where it transmits health information electronically in connection with an insurance transaction — so for much of this market the law most buyers assume applies is the one that does not.
9 min read - Evidence
REDEFINE 2 Explained: What CagriSema Does in Type 2 Diabetes
REDEFINE 2 randomized 1,206 adults with type 2 diabetes three to one against placebo and returned a weight difference of 10.4 percentage points — against 17.3 points for the same combination in people without diabetes, and 11.6 points for tirzepatide in the matching diabetes trial.
8 min read - Evidence
STEP 9 Explained: Semaglutide and the Arthritic Knee
STEP 9 randomized 407 people with obesity and moderate knee osteoarthritis two to one to semaglutide 2.4 mg or placebo. The WOMAC pain difference was 14.14 points, with a 95% interval running from 19.98 down to 8.30 — and rescue analgesic use was 4.9% against 5.1%.
8 min read - Evidence
SURPASS-3 Explained: Tirzepatide Against Titrated Insulin
SURPASS-3 randomized 1,444 insulin-naive adults with type 2 diabetes to tirzepatide or insulin degludec titrated to a glucose target. Tirzepatide won on glucose and weight — and its MRI substudy shows the insulin arm gaining thigh muscle while tirzepatide lost 0.64 liters of it.
10 min read - Evidence
ATTAIN-1 Explained: 11.2% at 72 Weeks, and the Columns That Reverse
ATTAIN-1 randomized 3,127 adults to orforglipron 6, 12 or 36 mg or placebo for 72 weeks. Weight loss rose at every dose step — but nausea and constipation peaked at 12 mg, and serious adverse events were lowest on the highest dose and lower than on placebo.
9 min read - Evidence
GLP-1s, Asthma and COPD: What the Observational Data Shows
Exacerbations run 48% lower than on a sulfonylurea — no different from an SGLT-2 inhibitor, and 24% higher than on metformin. The only randomized trial, in 40 people, did not move FEV₁ at all.
10 min read - Evidence
GLP-1s and Low Testosterone: Which Number Actually Moves
Total testosterone rises on this class. Free testosterone, the active fraction, often does not — because most of the rise is the carrier protein returning. And in men who did not start low, free testosterone fell.
10 min read - Evidence
GLP-1s and Men: What the Trials Actually Measured
The weight-loss trials were 63% to 81% women. The cardiovascular outcome trial was 72.5% men. Pooled across 19,906 patients men lost 6.8% against 10.9% — and got exactly the same reduction in cardiovascular events.
9 min read - Evidence
GLP-1s and Migraine: The Pressure Theory and Its Limits
Obesity raises migraine risk 27%, and one open-label pilot in 31 patients cut monthly headache days by nine. But there is no randomized trial, infused GLP-1 caused no headache at all — and the only national measurement found an effect in women and none in men.
9 min read - Formats
GLP-1 Denials and Appeals: The Levels, Rates and Deadlines
Medicare Advantage insurers overturned 80.7% of the prior-authorization denials that were appealed in 2024. Only 11.5% of denials were appealed, and the commonest reason given for not bothering is the one the data contradict.
9 min read - Formats
Employer GLP-1 Coverage: What the Surveys Actually Show
Coverage at the largest employers jumped from 28% to 43% in a year. Among large firms that do not cover it, 1% call themselves very likely to start and 67% say not likely — so the trend and your odds point different ways.
8 min read - Evidence
GLP-1 Injection Technique: What the Labels Specify, and What They Leave Open
Injection speed changed pain in neither randomized trial that measured it, and no label records a difference in exposure between abdomen, thigh and arm. Rotation is the rule that carries real evidence — all of it from insulin, and it shrinks sharply when randomized.
9 min read - Formats
Medicare and Medicaid GLP-1 Coverage: The Rule and Its Exceptions
The statute excludes agents used for weight loss, not the drugs themselves — which is why the same injectable sits on over 90% of Medicare formularies and is barred when the prescription says obesity.
9 min read - Evidence
Needle Fear and GLP-1 Injections: What the Evidence Measures
Exposure therapy cuts needle fear by a standardized mean difference of 1.09 right after treatment and 0.28 a year later — while the one result that holds at twelve months treats fainting, not fear. And the two cohorts comparing oral to injected semaglutide rank them in opposite orders.
9 min read - Safety
Importing a GLP-1 From Abroad: What the Rules Actually Say
FDA's personal importation policy is an internal instruction about enforcement discretion, not a permission, and its central condition is that effective treatment be unavailable domestically. The counterfeit Ozempic that reached Americans was seized inside the regulated U.S. supply chain.
10 min read - Safety
When the Pharmacy Changes: Why Two Compounded Vials Are Not Interchangeable
Generic substitution works because the FDA makes five findings first. None of them exists for a compounded preparation — and in approved generics, where all five do exist, merely changing a pill's color raised the odds of stopping by 34%.
9 min read - Formats
GLP-1 Prior Authorization: What It Requires and What It Costs
Medicare Part D coverage of these drugs climbed above 90% while the share of plans demanding prior authorization went from under a quarter to about 83% in four quarters. The gate moved; it did not open.
9 min read - Safety
A Power Outage and a GLP-1 in the Refrigerator: What the Labels Allow
Twelve hours without power spends about 2% of a 21-day unrefrigerated allowance, so duration is almost never what disqualifies a dose. What disqualifies one is a ceiling — and only one of the four approved labels says what happens when it is passed.
8 min read - Evidence
GLP-1 vs Liraglutide: What the Older Molecule Still Has
Liraglutide loses the head-to-head on weight and sits third-line in the current guideline. What it holds instead is three years of randomized follow-up, the only trial in children under 12, and eight generic manufacturers.
10 min read - Evidence
GLP-1 vs Orlistat: The 37% That Applied to a Fifth of the Trial
Orlistat's four-year trial cut diabetes incidence from 9.0% to 6.2%. Its own corrected conclusion says that difference was detectable only in the 21% with impaired glucose tolerance — while weight loss was the same in both subgroups.
9 min read - Safety
Who Actually Regulates a Compounding Pharmacy
State boards hold day-to-day oversight, FDA's authority is surveillance and for-cause, and the standards are written by a private convention. On FDA's own list of compounding actions, 183 of 392 entries for 503A pharmacies end in a letter to the state board — against zero of 77 for outsourcing facilities.
10 min read - Evidence
OASIS 1 Explained: 15% From a Tablet Nobody Sells
OASIS 1 escalated 334 adults to oral semaglutide 50 mg for 68 weeks and reported a treatment difference of 12.7 percentage points against placebo. The same 5% endpoint returns odds of 12.62 or 55.21 depending on which analysis is quoted — and the 50 mg strength never reached the market.
9 min read - Evidence
Once-Monthly GLP-1 Candidates: What the Trials Show
Two compounds are being tested on a monthly schedule, and neither can be bought. In the published phase 2, gastrointestinal side effects fell with slower dose escalation rather than with fewer injections — and the same doses produced roughly a third less weight loss in participants who also had type 2 diabetes.
9 min read - Evidence
Oral Tirzepatide: What Exists, and What Is Being Sold
No oral tirzepatide is approved anywhere and no trial of one is registered. The only published study giving tirzepatide by mouth was run in mice. Forty-three sellers tracked here list one for sale, and 18 of the 40 that price both routes charge more for the oral.
9 min read - Evidence
Retatrutide vs Tirzepatide: A Comparison That Reverses
Quoted from their own trial headlines, retatrutide leads tirzepatide by 3.3 percentage points. Standardized to one year and graded for certainty, it sits below tirzepatide in a band two certainty grades lower.
9 min read - Evidence
Rybelsus vs Injectable Semaglutide: One Molecule, Two Routes
The tablet and the weekly shot reach nearly the same average blood concentration — 77 against 75 nmol/L. Ninety percent of patients on the tablet land between 27 and 186 nmol/L, against 51 to 110 on the injection.
9 min read - Evidence
SURPASS-4 Explained: A Glucose Trial People Quote for Its Heart Column
SURPASS-4 randomized 2,002 people with type 2 diabetes and high cardiovascular risk to tirzepatide or titrated insulin glargine. Its primary endpoint was glycated hemoglobin. Its cardiovascular hazard ratio of 0.74 rests on 109 events — and its deaths ran 15, then 2, then 8 across three dose arms.
10 min read - Evidence
SURPASS-CVOT Explained: Noninferior to a Drug That Already Works
SURPASS-CVOT randomized 13,299 patients to tirzepatide or dulaglutide 1.5 mg and returned a hazard ratio of 0.92 whose interval stopped at 1.01 — superiority missed at P = 0.09. The pre-specified kidney analysis, run on the same randomization, cleared its bar at 0.77.
9 min read - Evidence
GLP-1 and Blood Pressure: Real, Rented, and Not Dose-Dependent
Twenty-four-hour monitoring found systolic pressure down 10.6 mmHg at the middle tirzepatide dose and 8.0 at the top one — where the diastolic fall was 0.5 mmHg on an interval crossing zero. Withdraw the drug and pressure climbs back 8.2 mmHg.
10 min read - Evidence
GLP-1 Body Composition: What the DXA and MRI Substudies Found
In the SURMOUNT-1 scan substudy, about 75% of the weight lost was fat and 25% was lean — on tirzepatide and on placebo alike. The drug changed the size of the loss, not its composition.
9 min read - Evidence
GLP-1 and Cholesterol: Which Column Actually Moves
At the highest labeled semaglutide dose, LDL moved 1.3% and 3.8% in the wrong direction against placebo while triglycerides fell 15.4% and 25.0% in the same two trials. More weight loss bought no LDL reduction at all.
10 min read - Evidence
Treating GLP-1 Constipation: What Has and Has Not Been Tested
The gastroenterology guideline gives its strong recommendations to polyethylene glycol and sodium picosulfate, conditional ones to fiber and magnesium, and no rating at all to docusate — which lost the only randomized trial it has. None of those trials enrolled anyone on a GLP-1.
9 min read - Evidence
Food Noise on GLP-1 Drugs: What Has Been Measured
The term reached advertising before it had a definition. In the one 60-week trial, food preoccupation fell against placebo at week 20 and not at weeks 40 or 60, while calories eaten stayed lower at all three visits.
9 min read - Evidence
GLP-1 and Set Point Theory: Moved, or Just Held Down?
Regain after stopping runs proportional to the loss — 9.69 kg pooled for semaglutide and tirzepatide — while weight on the drug held at −10.2% for 208 weeks. Neither result is what a reset set point looks like.
9 min read - Formats
Cancellation and Refund Terms: What Cancel Anytime Means
A September 15, 2026 snapshot of 257 reviews recorded no exit terms in 161. Compare cancellation, refunds and remaining commitments without treating missing review language as provider silence.
8 min read - Formats
How GLP-1 Sellers Advertise a Price
Six recurring devices across 257 written-up sellers and 1,108 recorded prices. An automatic plausibility screen flags 2.4% of numeric prices, all extreme figures.
8 min read - Evidence
GLP-1 vs GIP: What the Second Receptor Really Adds
Tirzepatide switches the GIP receptor on and reaches −20.2%. Maridebart cafraglutide blocks it and reaches −16.2%. Infused into people alongside GLP-1, GIP made them eat more, not less.
9 min read - Formats
What a Compounding Pharmacy Charges
Injectable semaglutide's estimated cost-based price is $0.89 to $4.73 a month. The oral tablet's is $38.62 to $72.49 — and across 803 compounded prices published here, oral runs dearer at retail too.
8 min read - Formats
What Your Money Buys in a Monthly GLP-1 Price
Six things might sit inside a monthly figure. In the September 15, 2026 sample of 257 reviews, the median settled one — and the item most often settled is the smallest.
8 min read - Evidence
How GLP-1 Drugs Work, and What the Mechanism Leaves Out
The delayed-stomach explanation is measurably temporary: gone by week 20 on semaglutide 2.4 mg, in the same trial where treated adults ate 35% less at a free lunch and had lost 9.9% of body weight.
9 min read - Evidence
OASIS 4 Explained: The 307-Person Trial Behind the Semaglutide Tablet
Three quarters of the oral semaglutide group reported a gastrointestinal event and 6.9% stopped the drug over one — against 5.9% on placebo. The trial's own registry posts two different answers to its primary endpoint.
9 min read - Evidence
REDEFINE 1 Explained: 3,417 People, and 302 in the Arm That Mattered
REDEFINE 1 put 2,108 participants on cagrilintide-semaglutide and 705 on placebo, and gave each single-drug arm 302. Both coprimary endpoints and all three confirmatory secondaries compared the combination against placebo.
9 min read - Evidence
STEP-HFpEF Explained: The Symptom Score That Ignored the Weight
Semaglutide improved symptoms by 7.8 points in heart failure with preserved ejection fraction. Its companion trial produced four points less weight loss and 7.3 points of the same benefit — and the placebo arm had twice as many serious adverse events.
10 min read - Evidence
SURMOUNT-MMO Explained: The Tirzepatide Outcome Trial That Has Not Reported
15,374 adults were randomized in October 2022 and primary completion is estimated for October 2027. No results are posted, so every cardiovascular figure quoted for tirzepatide comes from an active-comparator trial, an imputed placebo, or a risk equation.
10 min read - Evidence
Vaccines and GLP-1s: A Census of What Nobody Has Measured
No human study has measured vaccine response during GLP-1 treatment, and the word vaccine appears zero times across six current labels. The one review on the subject argues responses could be blunted; the human data on obesity points the other way, until the endpoint changes from antibodies to illness.
9 min read - Evidence
GLP-1 Abdominal Pain: One Reaction, Six Definitions
The semaglutide weight label reports abdominal pain at 20% against 10% on placebo. The diabetes label, same molecule, reports 5.7% against 4.6% — because one row counts seven terms and the other counts one.
9 min read - Evidence
GLP-1 Aspiration Risk: A Surrogate That Quadrupled, an Outcome That Did Not
Across 23 studies and 262,018 patients, retained gastric contents at endoscopy came out at an odds ratio of 4.54 on a GLP-1. Aspiration pneumonia in the same patients came out at 0.96.
9 min read - Evidence
GLP-1s After Cancer: What the Warning Covers, and What Nobody Measured
The boxed warning names medullary thyroid carcinoma and MEN 2, and no label mentions any other cancer. Every large cohort reporting lower cancer risk excluded people with a cancer history by design — and in the one survivor cohort, weight loss was 2.6% at a year.
9 min read - Evidence
Eating Out on a GLP-1: What the Timing Data Actually Show
At 12 weeks, semaglutide slowed first-hour gastric emptying to a ratio of 0.73. At 20 weeks and a higher dose, five-hour absorption was 8% faster than placebo. The difficult evenings track dose escalation, not the menu.
9 min read - Safety
GLP-1s and Air Travel: Cabin Pressure, Dry Ice and a Thin Evidence Base
The cabin is certified to 8,000 feet, dry ice is capped at 5.5 pounds with airline approval, and semaglutide is still in circulation five weeks after a dose. The air-travel literature for injectable therapy is 61 publications, 47 of them expert opinion.
8 min read - Evidence
GLP-1s and HIV: A Small Literature at Half the Dose
One randomized trial of 108 people at a single site, one single-arm study of 49, and both capped at 1.0 mg weekly against a labeled maintenance dose of 2.4 mg. No label names an antiretroviral, and no interaction study has been published.
9 min read - Evidence
How Much Water on a GLP-1: The Advice With No Number Behind It
All six labels in this class give the same two fluid sentences, and neither contains a quantity. The only volume any of them names is a four-ounce ceiling for swallowing a tablet — and the popular 2.7 and 3.7 liter figures were set at the median of what Americans already drank.
9 min read - Evidence
GLP-1 Hypoglycemia: The Population Nobody Counted
In semaglutide monotherapy, hypoglycemia at the 70 mg/dL threshold ran 0% on placebo and 3.8% on drug — while the confirmed 56 mg/dL row in the same table ran 1.6% on placebo and 0% on both doses. In adults without diabetes, both labels state the event was never systematically captured.
8 min read - Evidence
GLP-1s and Liver Impairment: What the Labels Do and Do Not Say
Three labels say no dose adjustment is needed in hepatic impairment. The fourth — the only one indicated to treat a liver disease — has no hepatic impairment section at all, and the reassurance behind the other three rests on single doses given to 25 and 19 people.
9 min read - Evidence
GLP-1s and Menstrual Changes: What Was Actually Measured
Six current labels record no human menstrual adverse reaction at all. The only measured cycle effect is in rats, at every dose, for both molecules — while the reporting databases split the same two molecules in opposite directions.
8 min read - Evidence
GLP-1s and Shift Work: Mostly Extrapolation, and Which Parts Are Not
The label says the time of day can change without any dose modification, and the half-lives are a week and five days. Everything else here is inference: the appetite hormone work used ten people on a laboratory schedule and seven night workers over three days, and no trial in this class has reported a result by shift status.
9 min read - Evidence
PIONEER 6 Explained: The Composite That Missed and the Deaths That Halved
PIONEER 6 cleared its safety margin and failed its superiority test — the registry records p = 0.1749 on the same hazard ratio of 0.79. Inside that composite, deaths fell by half while heart attacks ran the other way, on 137 events in sixteen months.
9 min read - Evidence
STRIDE Explained: 13% Further, and It Was Not the Weight
STRIDE improved treadmill walking distance in claudication by an estimated treatment ratio of 1.13 — about 24 meters on a 186-meter baseline. The gain was flat across body-mass index and blood sugar strata, and had shrunk to 1.08 five weeks after the last dose.
10 min read - Evidence
SURPASS-2 Explained: The Head-to-Head Ran at the Diabetes Dose
Tirzepatide beat semaglutide on glycated hemoglobin and weight at every dose in SURPASS-2. The comparator was semaglutide 1 mg rather than 2.4 mg, the trial was open-label, and every safety column in its posted results runs the other way.
10 min read - Safety
What an FDA Warning Letter Actually Means
FDA's own manual calls a warning letter informal and advisory, and says the agency does not treat it as final agency action. It alleges violations, it does not find guilt — and its absence proves far less than most readers assume.
9 min read - Evidence
Amycretin: What the Published Trials Actually Show
The amylin and GLP-1 co-agonist now called zenagamtide has produced the largest weight figure in this literature — out of a study whose primary endpoint was a count of side effects. Where the program was powered on efficacy, a hundredfold dose increase roughly doubled the effect.
10 min read - Evidence
ESSENCE Explained: An Interim Read on a Trial That Ends in 2029
ESSENCE randomized 1,197 patients with steatohepatitis and fibrosis stage 2 or 3 for 240 weeks. What has been published is a planned interim at week 72 in the first 800, reporting what pathologists saw on slides — and the endpoint that matters, cirrhosis-free survival, is due in 2029.
10 min read - Evidence
EVOKE and EVOKE+: The Alzheimer's Trials Read Out
Two phase 3 trials of oral semaglutide in early Alzheimer's disease enrolled 3,808 people across 40 countries and found nothing. The point estimates from the two identically designed trials landed on opposite sides of zero.
10 min read - Safety
GLP-1s and Dental Work: What the Sedation Warning Covers
Every labeled warning in this class is scoped to general anesthesia or deep sedation, and almost no dentistry reaches either. At the depth dental offices actually use, oxygen desaturation did not rise — the odds of needing an antiemetic nearly doubled.
9 min read - Evidence
GLP-1 and Smoking: What the Trials Found
Every randomized trial that prespecified an abstinence endpoint has missed it — 63% against 65% in the largest. What moved was post-cessation weight, and in the one trial followed to a year, even that advantage was gone.
10 min read - Formats
What a GLP-1 Costs Once You Reach a Maintenance Dose
The labels list three maintenance doses per molecule, and on one published ladder they cost $3,835, $5,135 and $7,085 a year. The sellers who discount a maintenance tier do it by capping the dose below anything the labels call maintenance.
8 min read - Safety
GLP-1 Dose Timing: What the Labels Actually Permit
Every approved injection says any time of day, with or without meals. Two labels fix the weekday and two do not. A systematic review screened a thousand papers looking for a better day and found no study that had ever compared two.
8 min read - Safety
State Telehealth Rules and Your GLP-1 Subscription
A seller's list of states is a compliance disclosure, not a marketing choice. California's statute says a questionnaire can be the required examination; Idaho's says a static online questionnaire alone is not a legitimate medical purpose.
9 min read - Safety
Switching From a Brand GLP-1 to a Compounded One
The dose number can move across intact. The concentration behind it, the device that measured it and the review that verified it do not — and since the shortages ended, a compounded product is lawful largely because it is not a copy.
9 min read - Evidence
Tapering Off a GLP-1: What Has Actually Been Tested
One randomized trial has compared lowering the dose against stopping, and its step-down arm never stepped down to zero. A quarter of those reduced to 5 mg still needed rescue therapy, against 8% who stayed at full dose and 67% on placebo.
9 min read - Formats
Cash Telehealth or a Clinic Visit: What Each Price Buys
Published compounded and brand price medians differ, but unmatched groups cannot isolate the cost of a visit. Compare medication, care, testing, and dispensing terms.
8 min read - Formats
Year Two on a GLP-1 Costs More Than Year One
Titration means a first year is spent mostly below the top dose. On one published dose ladder, year two costs 18.4% more than year one against an unchanged price list — and the sellers who re-price by dose advertise below the ones who do not.
8 min read - Evidence
STEP 8 Explained: The Head-to-Head, and the Column Nobody Tested
STEP 8 put weekly semaglutide against daily liraglutide in 338 adults and produced a 9.4-point weight difference that was tested and an adherence gap that was not. The protocol had already given the two arms different ways out, and the placebo arm quit more than the drug arm did.
9 min read - Evidence
SURMOUNT-3 Explained: The Lifestyle Lead-In Was a Filter
SURMOUNT-3 gave 806 adults twelve weeks of intensive dietary counseling and randomized only the 579 who lost at least 5%. Tirzepatide then took off a further 18.4% against a placebo arm that regained 2.5% — and the trial's authors note that nobody the program failed ever reached randomization.
10 min read - Evidence
SUSTAIN-6 Explained: A Safety Trial Read as a Benefit Trial
SUSTAIN-6 was powered to prove semaglutide did not raise cardiovascular risk in type 2 diabetes, and it cleared that bar. The 26% reduction it is quoted for came from a superiority test the trial's own results posting calls post hoc, in a composite whose mortality component did not move.
10 min read - Safety
What a LegitScript Certification Actually Proves
It certifies a root domain, it costs $975 to apply and $2,150 a year, and its stated purpose is card-not-present payments and advertising approval. Of 220 GLP-1 sellers written up here, 27 claim it — in five shapes that are not equally checkable.
8 min read - Safety
GLP-1s and ADHD Stimulants: What Nobody Has Measured
No published study pairs a GLP-1 with an ADHD stimulant, and neither drug class appears in the other's label. What the labels do show is that heart rate rises with both and blood pressure moves in opposite directions — so the reading most likely to be taken is the one least likely to show anything.
9 min read - Evidence
GLP-1 Ileus and Bowel Obstruction: What the Labels Say
Ileus and intestinal obstruction sit in the postmarketing section of every label with no incidence attached — and the two syntheses that looked hardest put liraglutide at an odds ratio of 3.00 and 0.44 for the same outcome.
9 min read - Evidence
GLP-1, Dehydration and Kidney Injury: Reading the Warning
Every label in the class warns about acute kidney injury from volume depletion, and the semaglutide label says it happened more often during dose titration — yet two meta-analyses of randomized tirzepatide data reach opposite conclusions about whether the risk exists.
9 min read - Evidence
GLP-1s and a History of an Eating Disorder: What Is Known
The Binge Eating Scale falls 8.14 points across five studies and 182 people. The same drug class returns binge eating at a reporting odds ratio of 2.70 in the FDA's adverse-event database — and no registered trial has ever studied it in anorexia nervosa.
9 min read - Evidence
GLP-1 and Heart Rate: How Many Beats, and Whether It Matters
Trials record a 1 to 4 bpm rise in resting heart rate — and 26% of treated adults hit a 20-beat swing against 16% on placebo — while the same drug class reduces death from any cause at a rate ratio of 0.88.
9 min read - Evidence
GLP-1s and IBD: What the Crohn's and Colitis Data Show
Zero randomized trials have been published in inflammatory bowel disease, and the observational record runs to 16,242 patients. The one study designed to emulate a trial found relapse at 7.9% against 7.9% — a relative risk of 1.01.
9 min read - Evidence
GLP-1s and Tacrolimus: The Interaction That Should Matter Most
Tacrolimus loses 37% of its exposure to a single high-fat meal, so a drug that slows the stomach should wreck it. Across 54,680 transplant recipients the troughs barely moved — but the mortality benefit that looks so clear in one subgroup disappears entirely in the next one along.
10 min read - Safety
GLP-1s and NSAIDs: The Kidney Risk Nobody Writes Down
No NSAID has ever been through a GLP-1 absorption study, and neither weight-management label names one. But the GLP-1 label warns of kidney injury after dehydration, the NSAID label says do not start in a dehydrated patient, and 74% of patients in the outcome trial already had the third leg of that triad.
9 min read - Evidence
GLP-1s and Osteoarthritis: What the Knee Trials Measured
STEP 9 cut WOMAC knee pain by 41.7 points. Its placebo arm, on diet and activity counseling alone, cut it by 27.5 — and the only other randomized trial in the class produced more weight loss and no pain benefit at all.
9 min read - Evidence
GLP-1s and Prediabetes: What Reversion Actually Buys
Semaglutide returned 81% of participants to normoglycemia against 14% on placebo — the largest categorical effect in this literature. A third to three-fifths of prediabetes reverts without any drug, and progression to diabetes explains under a quarter of the risk the label carries.
9 min read - Evidence
GLP-1 Rash and Hypersensitivity: What the Labels Record
Hypersensitivity reactions are a labeled common adverse reaction on tirzepatide at 5% against 3% on placebo — while adult semaglutide carries no rash or urticaria rate at all, and the class reports fewer skin events than DPP-4 inhibitors.
9 min read - Evidence
GLP-1s and Statins: Three Studies, Three Directions
Dulaglutide cut atorvastatin exposure 21%. Oral semaglutide raised rosuvastatin exposure 41%, outside the prespecified window. Neither changed a label — and the weight loss itself moves triglycerides by 15% while LDL cholesterol moves 2% to 4%, or the wrong way entirely in people with diabetes.
9 min read - Evidence
GLP-1 vs Contrave: The Trial That Was Stopped Before It Could Answer
Naltrexone-bupropion's cardiovascular trial read as a 41% risk reduction at its first interim look and as nothing at its second. The sponsor leaked the first one, and the trial never reached the point where the question could be answered.
9 min read - Evidence
GLP-1 vs Phentermine: The Drug That Ranked First, Then Last
Phentermine-topiramate was the single most effective weight drug in a 2024 network meta-analysis and the weakest of the well-evidenced agents in the 2026 one. Its own estimate moved by a tenth of a percentage point.
9 min read - Evidence
Weekly vs Daily GLP-1 Injections: What the Interval Actually Buys
The one randomized head-to-head gives the weekly drug a 9.4-point weight advantage and half the dropout. Gastrointestinal side effects were 84.1% against 82.7%, and only one arm was allowed to reduce its dose instead of quitting.
9 min read - Evidence
Survodutide and Mazdutide: What the Trials Show So Far
Two GLP-1 and glucagon dual agonists with phase 3 weight results in print. Survodutide's phase 3 came in below its phase 2, its liver trial's top dose was the worst of three, and neither compound has an FDA-approved product.
10 min read - Safety
GLP-1s and Acid Reducers: What a PPI Does to the Tablet
Omeprazole raised oral semaglutide exposure 13%, not lowered it, and the one clinical comparison found a larger HbA1c drop with a PPI than without. The real collision is the morning schedule: both drugs want the same pre-breakfast window.
9 min read - Evidence
GLP-1 Bloating: The Weakest Signal on the Whole GI Table
Abdominal distension was reported by 7% on semaglutide 2.4 mg against 5% on placebo — a pooled relative risk of 1.42, the smallest in the panel. Belching in the same trials came out at 7.88.
8 min read - Evidence
GLP-1 Dry Mouth: A Ten-Fold Ratio on a 1% Count
The tirzepatide label records dry mouth in 1% of treated patients against 0.1% on placebo. The semaglutide label, which counts down to 2%, never uses the term — and the dedicated human literature is three case reports.
8 min read - Evidence
GLP-1 Headache: How Much Is the Drug, and How Much Is Placebo
Headache is listed among liraglutide's most common adverse reactions at 13.6% — against 12.6% on placebo. Tripling the semaglutide dose moves it one point, and the tirzepatide obesity table omits it entirely.
9 min read - Safety
GLP-1s and Insulin: The Dose Reduction the Label Asks For
On the same 1 mg dose, documented symptomatic hypoglycemia ran 3.8% alone and 29.8% added to basal insulin. Against intensified insulin instead of placebo, pooled events ran at RR 0.46 — and the label's instruction is to change a prescription nobody at a cash intake holds.
9 min read - Safety
GLP-1s and Sulfonylureas: The Interaction That Reaches the Hospital
Hypoglycemia below 54 mg/dL ran 13.8%, 9.9% and 12.8% across three tirzepatide doses — flat. Split the same trial by whether a sulfonylurea was present and it runs 10.3% against 2.1%. The variable is the tablet, not the injection.
9 min read - Evidence
GLP-1 Vomiting: Rates by Dose, and a Ratio That Inverts
Vomiting was reported by 24% on semaglutide 2.4 mg and 13% on tirzepatide 15 mg — yet tirzepatide's pooled relative risk is 13.23 against semaglutide's 4.21, because the placebo arms differ threefold.
9 min read - Safety
GLP-1s and Warfarin: How Thin the Evidence Really Is
Four pharmacokinetic studies found no meaningful change, and the two that measured INR found slightly less anticoagulation. The published case literature on tirzepatide is two reports that disagree about the direction — and for the DOACs there is nothing at all.
9 min read - Safety
When a GLP-1 Arrives Warm: What the Labels Permit
The word “excursion” appears once across the four approved GLP-1 labels, and it belongs to a tablet. Meanwhile 75% to 100% of cold-chain shipments studied had been exposed to freezing — the one condition every label treats as disqualifying.
8 min read - Evidence
GLP-1 Needles: Length, Gauge and What Actually Reaches Muscle
An 8 mm needle at 90 degrees carries an estimated 25% intramuscular risk at the thigh against 1.6% for a 4 mm — and the people most exposed by a long needle are the leanest, not the heaviest.
8 min read - Formats
Prepay Rungs and Membership Fees: What They Add
Across 1,108 recorded price rows, 271 rise when current published figures are normalized for product and billing terms — by a median of $41 a month. The cheapest quartile gains 46.5%; the dearest gains 8.8%.
8 min read - Evidence
Vial or Pen: What the Error Data and the Labels Say
Compounded GLP-1 reports carry 48.9 times the reporting odds of a preparation error — and 0.24 times the odds of a dosing error. The failure is upstream of the syringe, and the multi-dose container is a different formulation.
9 min read - Evidence
STEP 3 Explained: Semaglutide Plus Thirty Counseling Visits
STEP 3 gave all 611 participants an eight-week low-calorie diet and thirty counseling visits. It produced semaglutide's largest weight figure and its smallest measured treatment difference, and those two facts have the same cause.
9 min read - Evidence
STEP 5 Explained: What the Second Year of Semaglutide Bought
STEP 5 ran semaglutide for 104 weeks. The treatment difference was −12.6 percentage points at week 52 and −12.6 at week 104: the second year held the result rather than extending it.
9 min read - Evidence
SURMOUNT-2 Explained: Tirzepatide With Type 2 Diabetes
SURMOUNT-2 randomized 938 adults with obesity and type 2 diabetes and reported −14.7% at 15 mg. A post hoc split at week 8 puts two-fifths of them at −21.2% and the rest at −11.2%.
9 min read - Evidence
SURMOUNT-OSA Explained: Two Trials, Split by the Machine
SURMOUNT-OSA randomized 469 adults across two parallel 52-week trials divided by whether they already used airway pressure. About half of those treated reached controlled disease, and the placebo arms were the ones that left.
9 min read - Evidence
GLP-1 Diarrhea: Rates, Molecules and the Dose Reversal
Diarrhea was reported by 30% on semaglutide 2.4 mg against 16% on placebo. Across three tirzepatide doses it climbed from 19% to 23% while constipation in the same patients fell from 17% to 11%.
8 min read - Evidence
GLP-1 Dizziness: Dehydration, Blood Pressure or Low Sugar
Dizziness ran 8% against 4% on placebo in the semaglutide trials and stayed flat at 4% to 5% across tripling tirzepatide doses. Semaglutide lowers systolic pressure by about 5 mmHg — but that is not what most of this is.
9 min read - Evidence
GLP-1 and Taste Changes: A Reward Shift, Not a Taste Loss
Trials recorded dysgeusia in 0.4% of tirzepatide patients. The one randomized test of taste acuity under semaglutide found it improved by 2.5 points on a 16-strip score, while reward response to food cues fell.
8 min read - Evidence
GLP-1 Injection-Site Reactions: What the Trials Recorded
Semaglutide recorded 1.4% against 1% on placebo; tirzepatide recorded 6% to 8% against 2%. Within the tirzepatide trials the reaction rate was 11.3% in patients with anti-drug antibodies and 1% in those without.
9 min read - Evidence
What Testing Found in Counterfeit GLP-1s
Products bought from illegal online sellers have been assayed. They carried more semaglutide than the label promised, under 15% purity, endotoxin in every sample — and in several clinical reports, insulin instead.
9 min read - Safety
The GLP-1 Shortage List, and What Ended It
A federal database entry is what made compounded semaglutide and tirzepatide lawful at scale. It was withdrawn in stages between October 2024 and May 2025, and what replaced it is a decision made one patient at a time.
9 min read - Evidence
Zepbound vs Mounjaro: Identical Doses, Different Approvals
Both brands list the same six tirzepatide strengths and the same 15 mg maximum, so there is no stronger version. The cardiovascular claim sits on the diabetes brand — and rests on noninferiority, not superiority.
9 min read - Formats
503A vs 503B: Two Rulebooks, One Word
Compounding is one word covering two statutory categories. They are exempt from different sections of the act, answer to different regulators, and leave behind different public records.
9 min read - Evidence
GLP-1 and Bone Density: What the DXA Scans Found
The arm that lost the most weight kept its bone density. Liraglutide alone finished below the exercise arm at hip and spine despite losing less weight — how the weight came off decided the result, not how much.
9 min read - Evidence
GLP-1 and Sleep: What the Research Actually Recorded
Sleep quality scores improved in one uncontrolled cohort of 78 patients — and the improvement did not track how much weight came off. The largest effect in this literature runs the other way entirely.
9 min read - Evidence
GLP-1 vs Metformin: The Cheap Drug's Fifteen-Year Record
Metformin took off a fraction of what semaglutide does, and in the one trial that followed people for fifteen years it was the arm that held the most weight off. Both halves of that sentence are load-bearing.
8 min read - Evidence
Wegovy vs Ozempic: Same Molecule, Two Different Labels
Ozempic tops out at 2 mg and Wegovy at 7.2 mg, yet neither label's indication list contains the other's — and the extra dose buys 3.1 percentage points while quadrupling one adverse event.
8 min read - Evidence
GLP-1 and Fatty Liver: What the MASH Biopsies Showed
ESSENCE resolved steatohepatitis in 62.9% of patients against 34.3% on placebo. The earlier trial resolved it in 59% against 17% and missed its fibrosis endpoint at P = 0.48 — two questions the same drug answered differently.
9 min read - Evidence
GLP-1 and Heart Failure: The HFpEF and HFrEF Split
In heart failure with preserved ejection fraction, semaglutide raised symptom scores 16.6 points against 8.7 on placebo. In reduced ejection fraction, two randomized trials found no benefit and more serious cardiac events.
9 min read - Evidence
GLP-1 vs Bariatric Surgery: What Each Route Has Been Shown to Do
Surgery takes off more weight and puts diabetes into remission where drugs do not. But the mortality comparison reverses between the pooled cohorts and the largest matched study, and nobody has ever been randomized to one or the other.
9 min read - Safety
What “Not FDA-Approved” Actually Means
The sentence on every review page describes five statutory findings that were never made about the vial. It is not a verdict on whether the drug works, and it is not boilerplate either.
8 min read - Formats
Can You Use an HSA or FSA for a GLP-1?
The rule turns on a disease diagnosed by a physician, not on the drug or the seller. The structures that make a telehealth plan cheapest to buy are the ones that make the qualifying portion hardest to prove.
8 min read - Formats
GLP-1 Savings Cards: Who Actually Qualifies, and What It Costs
The $25 copay card works only if commercial insurance already covers the drug. The self-pay price anyone can use is $349 for Wegovy and $299 to $449 for Zepbound — and a month, in both programs, means 28 days.
8 min read - Evidence
GLP-1s for Adolescents: What STEP TEENS Actually Showed
Semaglutide is approved from age 12, and the adolescent trial cut BMI by 16.1% against a 0.6% rise on placebo. The placebo teenagers gained 2.7% of their body weight over the same 68 weeks — which is why the teen and adult percentages do not stack.
9 min read - Evidence
GLP-1 for Alcohol Use Disorder: How Strong Is the Case?
The receptor work is genuinely persuasive and the registry hazard ratios are enormous. The randomized trials keep missing their primary endpoints, and the approved medications for this condition already have a number needed to treat.
8 min read - Evidence
GLP-1s and Athletes: Lean Mass, Strength and the Doping Rules
Lean mass fell 2.3 kg in one substudy while lean mass as a share of body weight rose 1.2 points. Resistance training is the only thing shown to move the ratio — and these drugs are monitored by WADA without being prohibited.
10 min read - Evidence
GLP-1s and Gastroparesis: The Signal and Its Denominator
The hazard ratio everyone quotes is 3.67, on a confidence interval running from 1.15 to 11.90. A later cohort of 313,342 matched pairs put every severe motility event at about 1% a year, and 55 randomized trials found nothing at all.
10 min read - Safety
GLP-1 Sharps Disposal: What the Rules Actually Require
Fifty-two injections a year and no single national rule. The same instruction is a recommendation in FDA guidance, an instruction on all four approved labels, and a statutory prohibition in California and Massachusetts.
8 min read - Safety
Flying With a GLP-1: TSA Rules and Dose-Day Math
TSA exempts medically necessary liquids and does not require a prescription label. The labels are less uniform: tirzepatide asks 72 hours between injections when the dose day moves, semaglutide 48.
8 min read - Evidence
GLP-1s and Type 1 Diabetes: The Off-Label Evidence
No GLP-1 is approved for type 1 diabetes, and people with type 1 and obesity take them anyway. In ADJUNCT ONE the 1.8 mg dose produced the largest weight loss and the only significant rise in ketosis — an event rate ratio of 2.22.
10 min read - Evidence
GLP-1 Cost Per Pound: The Comparison Nobody Runs
At this site's median compounded prices and the published trial means, semaglutide works out at about $80 a pound and tirzepatide at about $82 — despite costing 37% more a month. Net of placebo the gap closes entirely, and a year after stopping the figure is $212.
8 min read - Evidence
Switching From Semaglutide to Tirzepatide: The Evidence
The big tirzepatide numbers were measured in people starting treatment. For someone already on semaglutide, the only cohort that split switchers by reason found 8.1% at a plateau and 2.9% after non-response.
8 min read - Evidence
SOUL Explained: Oral Semaglutide and Heart Outcomes
SOUL cut major cardiovascular events from 13.8% to 12.0% over four years in adults with type 2 diabetes and established disease. The benefit tracked blood sugar, not weight, and the tablet it tested is 0.8% bioavailable.
10 min read - Evidence
STEP 1 Explained: The Trial Behind the 14.9% Figure
STEP 1 randomized 1,961 adults at week 0, before anyone had taken a dose, and reported its result under an estimand that counts the people who stopped. Both facts change what the headline percentage means.
9 min read - Evidence
STEP 2 Explained: Why the Same Dose Gave 9.6%
Semaglutide 2.4 mg for 68 weeks produced −9.6% in adults with type 2 diabetes and −14.9% in adults without it. The dose is identical; the eligibility criterion is the whole difference.
10 min read - Evidence
SURMOUNT-1 Explained: Inside the Tirzepatide Trial
Four parallel arms rather than a dose ladder, a substudy showing the same fat-to-lean ratio on placebo, a plateau reached by week 36 in most participants, and seventeen weeks off treatment that almost nobody quotes.
10 min read - Formats
Why GLP-1 Prices Range From Under $80 to Over $600
Across 450 published compounded semaglutide prices the full range is roughly fiftyfold — but five of the cheapest rows are insurance copays and the dearest are bundles. Set those aside and the real spread is 2.9-fold, driven by things a price never discloses.
8 min read - Evidence
GLP-1 Fatigue: A Signal That Sorts by Agent, Not by Class
Across 262 trials and 99,791 participants, the fatigue increases named belong to naltrexone-bupropion, orforglipron and CagriSema — not to weekly semaglutide or tirzepatide. Nothing measured tiredness properly, and that gap is the finding.
9 min read - Evidence
CagriSema: What the REDEFINE Trials Actually Found
Cagrilintide plus semaglutide reached −20.4% at 68 weeks and met both coprimary endpoints. Head to head against semaglutide alone the increment was 6.5 percentage points, and in diabetes the glycemic gain was 0.16.
9 min read - Evidence
GLP-1 Constipation: The Mechanism Does Not Survive Measurement
Constipation outlasts the nausea and is usually blamed on a slowed gut. At the maintenance dose no gastric-emptying delay was detectable, and the one study to measure colonic transit under a GLP-1 analog found it faster, not slower.
8 min read - Evidence
GLP-1s and Reflux: The Risk Reverses on Half-Life
Erosive reflux disease runs at a hazard ratio of 1.15 across the class — and 0.994 for the long-acting weekly drugs that telehealth actually sells. Meanwhile a 13 kg weight loss cleared reflux completely in 65% of people.
9 min read - Formats
Semaglutide Patents: What Expires, Where, and When
Generic semaglutide is marketed in Canada and India already. Every one of those approvals is the type 2 diabetes pen, the US substance patent runs to December 2031, and no approved US generic exists.
8 min read - Safety
GLP-1 Sulfur Burps: A Top Signal With No Study Behind It
Belching tops the disproportionality table for both semaglutide and tirzepatide reports, and sits nowhere on the frequency table. No trial has ever measured it as an endpoint, and nothing has measured what a belch contains.
8 min read - Evidence
Orforglipron: What the Phase 3 Trials Show, and Its Status
The first non-peptide oral GLP-1 was approved in April 2026. It beat oral semaglutide on blood sugar and had half again the gastrointestinal events, and its label's milligrams are not the milligrams in the papers.
9 min read - Evidence
Retatrutide: What the Trials Show, and Why You Cannot Buy It
The triple agonist reached −24.2% body weight at 48 weeks in phase 2, and no product containing it is approved anywhere. Assays of vials sold online as research peptides found 7.7% to 14.37% purity against a 99% label claim.
9 min read - Evidence
FLOW Explained: The Semaglutide Kidney Outcomes Trial
FLOW randomized 3,533 adults with type 2 diabetes and kidney disease and was stopped early: 331 major kidney events against 410, a hazard ratio of 0.76. What it says about everyone else is a weaker claim.
9 min read - Evidence
GLP-1s and Antidepressants: What the Subgroup Data Show
In STEP 1 the participants already on an antidepressant lost 15.7% against a placebo arm that lost 0.2%. The weight loss holds — but the trials excluded anyone in an active episode, and that is the part that travels.
9 min read - Safety
GLP-1s and Caffeine: What Has Actually Been Studied
No trial has given caffeine to anyone on semaglutide or tirzepatide. What exists is four decades of work on caffeine and the stomach, and one measurement in a related peptide where exposure went down.
9 min read - Safety
GLP-1s and Levothyroxine: The Interaction on the Label
Thyroxine exposure rose 33% with the semaglutide tablet, and weight loss cuts the dose a body needs. In the one outcome study of people already on levothyroxine, atrial fibrillation ran higher — and thyroid testing did not change at all.
9 min read - Safety
GLP-1s and Oral Medications: What the Interaction Trials Found
Delayed gastric emptying is assumed to cut absorption. The measured exposure changes that reached significance were increases, the peak is what reliably falls, and the labels name exactly two drugs.
9 min read - Evidence
SELECT Explained: The Semaglutide Cardiovascular Trial
SELECT randomized 17,604 adults with heart disease and no diabetes. Events fell from 8.0% to 6.5%, a hazard ratio of 0.80 — and a prespecified analysis found the protection did not follow the weight lost.
9 min read - Evidence
STEP 4 Explained: What Happens When Semaglutide Stops
After a 20-week run-in, 803 adults were randomized to continue semaglutide or switch to placebo. Over the next 48 weeks the two arms moved −7.9% and +6.9% — a gap of 14.8 percentage points.
9 min read - Evidence
SURMOUNT-4 Explained: Stopping Tirzepatide, Measured
After a 36-week lead-in that removed a mean 20.9%, 670 adults were randomized to continue tirzepatide or switch to placebo. The two arms then moved −5.5% and +14.0%.
9 min read - Evidence
GLP-1 After Bariatric Surgery: The Regain Evidence
One randomized trial covers this: 70 adults, liraglutide, a mean difference of −8.03% over 24 weeks. Everything else is cohorts, and the tirzepatide trial has not reported.
9 min read - Evidence
GLP-1s After 65: What the Age-Specific Evidence Shows
The dedicated literature on adults aged 65 and over is five studies and 1,229 participants. Efficacy looks ordinary; the questions about muscle, falls and polypharmacy are the ones nobody has answered.
8 min read - Evidence
GLP-1s and PCOS: What the Evidence Actually Shows
Eleven randomized trials, most of them tiny, in women with PCOS and obesity. Weight falls. Androgens improve against placebo but not against metformin — and every fertility result was measured after the drug was stopped.
9 min read - Evidence
GLP-1 and Menopause: What the Transition Actually Changes
In the SWAN cohort the rate of weight gain did not accelerate at the menopause transition at all. What doubled was the rate of fat gain, while lean mass started falling — and that second change is where a GLP-1 gets expensive.
8 min read - Evidence
GLP-1 Doses and Acute Illness: What the Evidence Actually Covers
Both labels warn that vomiting and diarrhea can cause acute kidney injury, and neither says whether to hold a dose. Formal sick-day rules exist for five other drug groups, and the one randomized test of holding medicines changed nothing.
8 min read - Evidence
“Ozempic Face”: What Imaging Measured, and What It Cannot Separate
One cohort scanned 20 faces and found 7% of midfacial volume lost per 10 kg — almost all of it superficial fat. No controlled study has shown a facial change these drugs cause beyond the weight they remove.
9 min read - Safety
Semaglutide and the Eyes: NAION and Retinopathy in Absolute Numbers
A referral clinic measured a 6.7% three-year NAION incidence. A national register measured 0.12% over five years. Both are real, and the gap between them is the whole story.
9 min read - Evidence
Do GLP-1s Cause Hair Loss? The Trials, and the Surgery Comparison
Alopecia ran 5.4% against 0.9% on placebo in the tirzepatide trials — but the risk is flat across doses, rises with the weight actually lost, and disappears when the comparator is bariatric surgery instead of another drug.
9 min read - Formats
What a Year on a GLP-1 Actually Costs
Thirteen four-week periods span 52 weeks. Compare billing periods, memberships and opening rates across a year, while keeping annualized rates separate from actual payment dates.
8 min read - Safety
GLP-1s Before Surgery: The Fasting Guidance, Revised
The 2023 advice was a blanket hold — a week for weekly drugs. In October 2024 five societies replaced it with risk stratification, and the evidence underneath explains why.
9 min read - Formats
GLP-1 Insurance vs Cash Pay: How the Two Routes Differ
Most of this market prices in cash because a compounded preparation never enters the formulary system. What coverage generally looks like for the approved products, and how to compare the two honestly.
8 min read - Safety
Missed a GLP-1 Dose: What the Four Labels Say
Ozempic allows five days, Zepbound and Mounjaro allow four, and Wegovy measures the window backward from the next dose instead. Same class, same molecule in two cases, different instructions.
7 min read - Safety
GLP-1 Storage: What Each Label Actually Allows
The refrigerated range is identical across all four approved injectables. The room-temperature allowance is not: 28 days on a Wegovy pen, 21 on a Zepbound or Mounjaro pen, 56 on an Ozempic pen already in use.
8 min read - Formats
GLP-1 Telehealth: Seven Patterns Worth Checking
A first-month rate, a membership quoted separately, a permanent anchor, an expired promotion, a dose named by a marketing word, no state list, no pharmacy. None is proof of anything; each is a question.
8 min read - Formats
How to Vet the Pharmacy Behind a Compounded GLP-1
The brand taking your order is usually not the one making the drug. Federal law splits compounders into two categories with different regulators, different rulebooks and different public records.
9 min read - Evidence
The GLP-1 Weight Loss Plateau: When Loss Slows and Stops
Weight loss ran on for about 65 weeks in the longest trial, then held for three more years. Raising the dose has been randomized once, and the extra loss came with a measurable price.
8 min read - Evidence
GLP-1 and Exercise: What the Training Trials Measured
Exercise alongside a GLP-1 has been randomized once. Adding a year of supervised training to liraglutide roughly doubled the fall in body-fat percentage, and the advantage was still visible a year after everyone stopped.
8 min read - Evidence
Eating on a GLP-1: Protein, Appetite and the Trial Diets
Semaglutide cut intake at a test lunch by 35%, which is the point of the drug and the reason adequacy gets hard. What the trial protocols fed people, and where the protein numbers actually come from.
8 min read - Safety
GLP-1s and Mental Health: Reading the Suicidality Evidence
A 2023 regulatory signal prompted large studies of suicidal ideation, self-harm and depression on these drugs. Most found no increase, with real imprecision and one large gap.
9 min read - Safety
GLP-1 and Thyroid Cancer: The Warning and the Data
The boxed warning comes from rodent studies with a receptor-mediated mechanism that primates largely lack. The human epidemiology since has disagreed with itself, and the absolute rates are small either way.
9 min read - Formats
What Is Actually in a Compounded GLP-1 Vial
Base form or salt form, a concentration rather than a dose, a preservative a single-use pen never needs, and the B12, NAD and L-carnitine blends the FDA says nobody has tested.
9 min read - Safety
GLP-1 and Alcohol: What the Craving Evidence Shows
Three randomized trials have now measured drinking on a GLP-1, and they disagree in an informative way. Whether it is safe to drink while taking one is a separate question, and the labels answer it by saying nothing.
8 min read - Evidence
GLP-1 and Kidney Disease: What the FLOW Trial Found
FLOW randomized 3,533 adults with type 2 diabetes and albuminuric kidney disease. Major kidney events occurred in 331 on semaglutide against 410 on placebo, a hazard ratio of 0.76.
8 min read - Evidence
GLP-1 and Sleep Apnea: What SURMOUNT-OSA Measured
Tirzepatide lowered the apnea-hypopnea index by 20.0 events per hour more than placebo in one trial and 23.8 in the other, from a baseline near 50 events per hour.
8 min read - Safety
GLP-1 Gallstones and Pancreatitis: The Absolute Rates
Two warnings sit side by side on the label with very different evidence behind them: the gallbladder signal is consistent and dose-related, while pancreatitis keeps failing to appear in randomized data.
9 min read - Evidence
GLP-1 Long Term: How Far the Evidence Actually Runs
The randomized horizon in this class is four years, and most of it is shorter. What held, what narrowed after treatment stopped, and how much attrition sits under every long-term percentage.
8 min read - Formats
Semaglutide Doses Explained: 0.25 mg to 2.4 mg
Five rungs, four weeks apart. What each milligram is for, which ones the label treats as destinations rather than waypoints, and why a compounded seller may not stock them all.
8 min read - Formats
Tirzepatide Doses Explained: 2.5 mg to 15 mg
Six rungs, 2.5 mg apart, and only three of them are approved maintenance doses. What each step is for, which ones the trials actually randomized, and what that means for a quoted price.
8 min read - Evidence
GLP-1 for Diabetes vs Weight Loss: Two Approvals, One Molecule
Semaglutide and tirzepatide each hold two separate approvals under different brand names, at different dose ceilings, measured against different endpoints. The same drug is not the same product.
8 min read - Evidence
How Much Weight Tirzepatide Took Off in the SURMOUNT Trials
SURMOUNT-1 put the mean at −15.0% on 5 mg and −20.9% on 15 mg over 72 weeks. Six percentage points separate the bottom rung from the top, and more than two in five on the highest dose never reached 20%.
9 min read - Safety
Compounded vs Brand-Name GLP-1: What Actually Differs
Compounded semaglutide is not a generic Wegovy. It is a preparation no agency has reviewed for safety, efficacy or quality before it reaches you.
6 min read - Evidence
GLP-1 for Women and Men: What Actually Differs
There is no women's formulation and no men's one. A 248-patient cohort found no difference by sex; a far larger pooled estimate finds men lose less weight — and one interaction differs enough to raise with a prescriber.
6 min read - Safety
GLP-1 Side Effects: What the Trials Recorded
Nausea and diarrhea lead, mostly during dose escalation, mostly mild to moderate — and between 4% and 7% of trial participants stopped because of them.
6 min read - Evidence
Tirzepatide vs Semaglutide: What the Trials Actually Measured
SURMOUNT-5 directly compared the two in adults with obesity without diabetes: average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks.
7 min read - Evidence
What Happens When You Stop Taking a GLP-1
Two randomized withdrawal trials measured it directly: 6.9% regained after stopping semaglutide, 14.0% after stopping tirzepatide.
6 min read - Evidence
GLP-1 and Muscle Loss: What Has Actually Been Measured
Pooled across 38 reports, muscle measures fell 1.41 kg against 6.02 kg of fat in adults without diabetes — under a fifth of the weight lost. The scanned population is a fraction of the weighed one.
8 min read - Evidence
GLP-1 and the Heart: What the Outcome Trials Found
SELECT randomized 17,604 adults with cardiovascular disease and obesity. Events occurred in 6.5% on semaglutide against 8.0% on placebo — a 20% relative reduction, and 1.5 percentage points in absolute terms.
9 min read - Formats
GLP-1 Microdosing: What the Dose Evidence Covers
Lower doses of semaglutide have been measured, and every one beat placebo. What has not been measured is the reduced weekly protocol sellers price under the word microdose.
8 min read - Safety
GLP-1 Nausea: When It Starts, Peaks and Settles
Nausea tracks the dose schedule, not the calendar. In STEP 4, 89% of participants climbed all the way to the maintenance dose — and once they were there, they stopped for side effects at the same rate as placebo.
7 min read - Safety
GLP-1s, Pregnancy and the Birth Control Interaction
These drugs are not for use in pregnancy, and the semaglutide label asks for a two-month gap before conception. Separately, tirzepatide changes how a swallowed contraceptive is absorbed — with a four-week rule that reopens at every dose step.
8 min read - Formats
GLP-1 Titration: The Dose Climb and What It Costs
Semaglutide takes 16 weeks to reach its maintenance dose and tirzepatide 20. That split — a short climb and a long plateau — is why a seller's dose-pricing policy outruns its opening price.
7 min read - Evidence
How Much Weight People Lost on Semaglutide in the Trials
STEP 1 put the mean at −14.9% over 68 weeks. Half the participants reached 15%, about one in three never reached 10%, and STEP 4 showed the weight coming back when the drug stopped.
8 min read - Formats
Oral vs Injectable GLP-1: What the Tablet Trials Show
Daily oral semaglutide reached −15.1% in its own trial and the weekly injection reached −14.9% in another. Three separate trials, no head-to-head, and no compounded tablet in any of them.
8 min read - Safety
Who Should Not Take a GLP-1: The Short List and the Long One
The formal contraindications fit in two lines: a medullary thyroid carcinoma or MEN 2 history, and a prior serious reaction to the drug. Everything else that circulates as a rule is a conversation, and the two are worth telling apart.
8 min read